Genetic Engineering

Universal Donor Stem Cells

TC BioPharm (TCB) is a biopharmaceutical business currently developing the closest to market drug candidate in Gamma Delta T (GDT) cell therapies. We have a strong focus on chimeric antigen receptor (CAR) modified GDT cells with the aim of treating cancer and major viral diseases. We have a unique technology with a demonstrable safety profile and established intellectual property rights for the entire GDT-based platforms - ImmuniCAR® and OmmniCAR®. This negates increasing concerns over the safety of current alpha beta CAR-T cell therapy approaches. Our proprietary culture media and manufacturing methods overcome the major barriers to commercialising GDT cell therapies, ensuring batch consistency.

We operate a GMP cell therapy manufacturing facility from headquarters near Glasgow. All regulatory, clinical and quality functions are performed in-house. We also have facilities in Edinburgh, London, and Kawasaki City (in the Greater Tokyo area).

GDT cells are naturally-occurring cells within the human body, inducing one of the first lines of defence against infectious disease. These cells are primed to attack and destroy ‘biologically-stressed’ cells: those either infected with virus/bacteria, or cancerous cells. They do this by detecting isopentenyl pyrophosphates (IPPs) on the surface of cells which have become stressed by transformation or infection.

We are creating ground breaking, pioneering, disruptive therapies with unrivalled applicability to a broad range of cancers and viral infections. This step-changing approach leverages the immense therapeutic and commercial potential of GDT cells by ‘pharmaceuticalising’ cell therapy, simplifying its ease of use, widening patient access and improving Quality of Life.

TCB has a number of partnership and licensing opportunities across its product platforms.Contact us for further information, including safety profiling and efficacy equivalence.